跳至主要内容
临床试验/2024-517314-15-00
2024-517314-15-00招募中4 期

IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS

Centre Hospitalier Universitaire Amiens Picardie1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年9月10日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
100
试验地点
1
主要终点
Carotid intima media thickness (CIMT)

研究概览

简要总结

To compare the CIMT after 3 months of therapy in ulcerative colitis in patients treated by anti-TNF, vedolizumab, and tofacitinib

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Ulcerative colitis evolving for at least 6 months
  • Patient older than 18 years
  • Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib
  • Patient covered by French national health insurance
  • Written informed consent

排除标准

  • Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period.
  • Patients with a cardiovascular event such as myocardial infarction and stroke
  • Diabetic patient
  • Pregnant women or breastfeeding
  • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

结局指标

主要结局

Carotid intima media thickness (CIMT)

Carotid intima media thickness (CIMT)

次要结局

  • Aortic pulse wave velocity (aPWV) / arterial stiffness
  • Augmentation index (AIx)
  • Framingham score, the 10-year atherosclerotic CV disease risk (ASCVD) indices (reflect of the cardiovascular risk) and the SCORE score
  • Ulcerative colitis activity score /Mayo Score
  • Lipids parameters (HDL, LDL, TC, TG)
  • Arterial tension and systolic pressure index
  • Endothelial function / Coagulation parameters

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

FUMERY MATHURIN

Scientific

Centre Hospitalier Universitaire Amiens Picardie

研究点 (1)

Loading locations...

相似试验